Bookmark and Share

Risperdal Consta Approved for Bipolar Disorder

MONDAY, May 18 (HealthDay News) -- The Janssen Pharmaceuticals drug Risperdal Consta (risperidone) has been approved by the U.S. Food and Drug Administration for people with Bipolar 1 disorder, the drug maker said Monday.

Risperdal Consta is the long-acting version of Risperdal, which was first FDA-approved more than a decade ago and is now sanctioned for Bipolar 1, schizophrenia and autism.

Type 1 bipolar disorder involves at least one manic episode, with or without a major depressive episode.

Approval of Risperdal Consta for Bipolar 1 was granted as a single therapy, or in combination with lithium or valproate, Janssen said in a news release.

As with similar antipsychotic drugs, the packaging for Risperdal Consta includes a warning that the drug is not approved for elderly people with dementia-related psychosis, and could increase their risk of death.

More information

The FDA has more about this drug's approval history.



Prescriptions DON'T HAVE Rx COVERAGE?
Click Here to print out your FREE OPTIMIZERx Card and instantly begin savings on your next prescriptions!
Send us Feedback!


Need to Sign up?
It's Easy and Free!



Signup & Save  

Already a Member?
Login Here!


Get Selected Offers

As a FREE member of our community,
you will have instant access to:


Click the Play Button to Learn More

Free Rx coupons, trial vouchers, samples & other special savings

Alerts on future savings & support on selected meds & health products

Health Savings Newsletters

Tips , videos & Information to better manage your health conditions

Community Forums


Close Window